e-learning
resources
Madrid 2019
Sunday, 29.09.2019
Treatment of asthma with monoclonal antibodies
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Switch Omalizumab – Mepolizumab: real life experience
D. Bagnasco (Genoa, Italy), F. Menzella (Reggio Emilia, Italy), M. Caminati (Verona, Italy), M. Bonavia (Arenzano, Italy), G. Guida (Turin, Italy), C. Caruso (Rome, Italy), G. Passalacqua (Genoa, Italy)
Source:
International Congress 2019 – Treatment of asthma with monoclonal antibodies
Session:
Treatment of asthma with monoclonal antibodies
Session type:
Poster Discussion
Number:
1656
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Bagnasco (Genoa, Italy), F. Menzella (Reggio Emilia, Italy), M. Caminati (Verona, Italy), M. Bonavia (Arenzano, Italy), G. Guida (Turin, Italy), C. Caruso (Rome, Italy), G. Passalacqua (Genoa, Italy). Switch Omalizumab – Mepolizumab: real life experience. 1656
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Related content which might interest you:
Omalizumab in severe asthma: real life study
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
Omalizumab in practice: learning from experience
Source: Annual Congress 2007 - Changing practice with anti-IgE: patient, physician and payor perspectives
Year: 2007
Real life experience with omalizumab and mepolizumab in severe asthma : do patient baseline features preclude effectiveness comparison ?
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
When omalizumab is effective, should treatment be for life?
Source: International Congress 2018 – Asthma management
Year: 2018
Late Breaking Abstract - Patients with severe eosinophilic asthma benefit from the treatment with Anti-IL-5 Reslizumab – a real life study from Austria
Source: International Congress 2018 – Notable Studies in Asthma
Year: 2018
Effectiveness evaluation of anti-IgE treatment at 3rd year: Real life Turkey data
Source: International Congress 2016 – Asthma points to ponder
Year: 2016
Long Term Sirolimus therapy for LAM: a real life experience
Source: International Congress 2017 – Rare diseases
Year: 2017
Real-world outcomes in patients receiving omalizumab for allergic asthma in India: Analysis by baseline IgE level
Source: Annual Congress 2013 –Treatment of asthma
Year: 2013
Asthma treatment in real life
Source: International Congress 2018 – Primary care management of asthma
Year: 2018
Tiotropium + olodaterol fixed-dose combination shows clinically meaningful improvements in quality of life versus placebo
Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Year: 2015
Late Breaking Abstract - Extrafine single inhaler triple therapy improves quality of life in COPD. Analysis of SGRQ subdomains of the TRIBUTE Study
Source: International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS
Year: 2018
Fluticasone propionate/formoterol therapy for asthmatic patients: Results of a non-interventional study
Source: International Congress 2016 – Asthma management
Year: 2016
Late Breaking Abstract - Durable clinical benefit of benralizumab following oral corticosteroid reduction: The PONENTE study
Source: Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments
Year: 2021
The real world effectiveness and effect on adherence with inhaled asthma therapy of 1 year of Severe Asthma Monoclonal Antibody Treatment
Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma
Year: 2020
Single inhaler triple therapy in patients with COPD: response rates in health-related quality of life in the IMPACT Trial
Source: International Congress 2018 – Clinical trials in COPD: new results
Year: 2018
Valuing the real world benefits of omalizumab
Source: Annual Congress 2007 - Changing practice with anti-IgE: patient, physician and payor perspectives
Year: 2007
Omalizumab improves asthma-specific quality of life in patients with severe allergic asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 37s
Year: 2001
Adherence to COPD controller therapy: real life setting
Source: International Congress 2019 – Inhalers: adherence and preference
Year: 2019
Use of Omalizumab in children in real clinical practice.
Source: Virtual Congress 2021 – Paediatric allergic asthma: novel therapeutics and monitoring approaches
Year: 2021
Uncovering the reality of life with severe asthma
Source: International Congress 2016 – Exploring mechanisms in health and disease
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept